Compare AMRC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | OGN |
|---|---|---|
| Founded | 2000 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2010 | 2020 |
| Metric | AMRC | OGN |
|---|---|---|
| Price | $31.31 | $13.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.88 | $11.40 |
| AVG Volume (30 Days) | 442.4K | ★ 14.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.49 | ★ 0.72 |
| Revenue | $1,769,928,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $10.71 | $0.45 |
| Revenue Next Year | $9.07 | $1.67 |
| P/E Ratio | $59.71 | ★ $18.42 |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $11.48 | $5.69 |
| 52 Week High | $44.93 | $13.39 |
| Indicator | AMRC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.52 | 78.82 |
| Support Level | $29.05 | $6.31 |
| Resistance Level | $34.29 | N/A |
| Average True Range (ATR) | 1.32 | 0.53 |
| MACD | 0.55 | 0.46 |
| Stochastic Oscillator | 97.17 | 98.00 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.